CompoAtlas

Dual-Tox DPO

On sale on the US market (according to the DSLD)

NuMedica, food supplement from the US market

Dual-Tox DPO (NuMedica), a food supplement au code-barres 812527012042, is described by its US market label. The French and European rules we can apply to this label flag no particular point. Doses of folates are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

If this product were sold in France

No point flagged by the rules we apply.

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
NuMedica
Barcode
812527012042
Form
Capsule
One serving
2 capsules
Servings
up to 2 servings per day
Other ingredients (in English, as written)
HPMC, MCC, Rice Flour
Ingredient (as written, in English)CategoryPer serving
Vitamin B-6Vitamin50 mg
FolateVitamin800 µg
Vitamin B12Vitamin200 µg
Artichoke leaf extractPlant600 mg
Watercress herb powderPlant500 mg
SilymarinOther substance250 mg
Alpha-Lipoic AcidOther substance200 mg
NACOther substance200 mg
Sodium SulphateOther200 mg
CatechinsOther substance150 mg
Ellagic AcidOther substance100 mg
MSMOther substance100 mg
Calcium D-GlucarateOther substance100 mg

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • NAC
    Read the warning, when it applies and the studies cited

    N-ACETYL-L-CYSTEINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney stones (Fauci et al. 1998; Mårtensson et al. 1990).

    Sources cited by Health Canada (2)
    • Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DI, Hauser SL and Longo DL, editors. Harrison's Principles of Internal Medicine, 14th edition. Toronto (ON): McGraw-Hill Health Professions Division; 1998.
    • Mårtensson J, Denneberg T, Lindell Å, Textorius O. Sulfur amino acid metabolism in cystinuria : A biochemical and clinical study of patients. Kidney International 1990;37:143-149. PubMed

    Contraindications

    Do not use if you are taking antibiotics or nitroglycerin (Repchinsky 2008; Cederlund and Märdh 1993; Parry and Neu 1977; Ardissino et al. 1997).

    Sources cited by Health Canada (4)
    • Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N- acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Journal of the American College of Cardiology 1997;29(5):941-947. PubMed Randomised trial
    • Cederlund H, Märdh PA. Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 1993;32:355-365. PubMed Review article
    • Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. Journal of Clinical Microbiology 1977;5(1);58-61.
    • Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Health Canada monograph dated 19 December 2025

  • MSM
    Read the warning, when it applies and the studies cited

    MSM

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Kim et al. 2005).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : NuMedica

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Dual-Tox DPO (NuMedica): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/812527012042-dual-tox-dpo-numedica, updated 25 July 2018.

List recorded in 2018. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line